checkAd
    Startseite > Aktien > Intec Pharma > Nachrichten
    Intec Pharma Aktie
    ISIN: IL0011177958 · WKN: A1C7WG · Israel

    Neueste Nachrichten

    Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
    04.06.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20
    03.06.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference
    30.05.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting
    29.05.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
    22.05.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    08.05.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
    11.04.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
    28.03.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
    25.03.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
    18.03.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
    13.03.24 · globenewswire · Intec Pharma
    Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
    04.03.24 · globenewswire · Intec Pharma